@article {Grewal2022.10.31.22281766, author = {Ramandip Grewal and Lena Nguyen and Sarah A Buchan and Sarah E Wilson and Sharifa Nasreen and Peter C. Austin and Kevin A. Brown and Deshayne B. Fell and Jonathan Gubbay and Kevin L. Schwartz and Mina Tadrous and Kumanan Wilson and Jeffrey C Kwong and Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators}, title = {Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes}, elocation-id = {2022.10.31.22281766}, year = {2022}, doi = {10.1101/2022.10.31.22281766}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background To inform planning for further booster doses of COVID-19 vaccines, we estimated the effectiveness of monovalent mRNA vaccines against Omicron-associated severe outcomes in adults over time.Methods We used a test-negative design and multivariable logistic regression to estimate vaccine effectiveness (VE; 2, 3, or 4 doses compared to unvaccinated individuals) and marginal effectiveness (3 or 4 doses compared to 2 doses) against Omicron-associated hospitalization or death among community-dwelling adults aged >=50 years who were tested for SARS-CoV-2 between January 2, 2022 and October 1, 2022 in Ontario, Canada, stratified by age group and time since vaccination. We also compared VE during periods of Omicron BA.1/BA.2 and BA.4/BA.5 sublineage predominance.Results We included 11,160 cases of Omicron-associated severe outcomes and 62,880 test-negative symptomatic controls. Depending on the age group, compared to unvaccinated individuals, VE was 91-98\% 7-59 days after a third dose, waned to 76-87\% after >=240 days, was restored to 92-97\% 7-59 days after a fourth dose, and waned to 86-89\% after >=120 days. Trends in marginal effectiveness were consistent with VE estimates. VE was lower during the BA.4/BA.5-predominant period compared to the BA.1/BA.2-predominant period based on the same intervals since vaccination.Conclusion Our findings suggest that 1 or 2 booster doses of monovalent mRNA COVID-19 vaccines initially restored very strong protection against Omicron-associated severe outcomes in all age groups, but VE subsequently declined over time with some age-related differences, and particularly so during a period of BA.4/BA.5 predominance.Competing Interest StatementKumanan Wilson is CEO of CANImmunize and serves on the data safety board for the Medicago COVID-19 vaccine trial. The other authors declare no conflicts of interest.Funding StatementThis work was supported by funding from the Canadian Immunization Research Network (CIRN) through a grant from the Public Health Agency of Canada and the Canadian Institutes of Health Research (CNF 151944), and also by funding from the Public Health Agency of Canada, through the Vaccine Surveillance Working Party and the COVID-19 Immunity Task Force. This study was supported by Public Health Ontario and by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH) and Ministry of Long-Term Care (MLTC). This work was also supported by the Ontario Health Data Platform (OHDP), a Province of Ontario initiative to support Ontario{\textquoteright}s ongoing response to COVID-19 and its related impacts. Jeffrey C. Kwong is supported by a Clinician-Scientist Award from the University of Toronto Department of Family and Community Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ICES is a prescribed entity under Ontario{\textquoteright}s Personal Health Information Protection Act (PHIPA). Section 45 of PHIPA authorizes ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system. Projects that use data collected by ICES under section 45 of PHIPA, and use no other data, are exempt from REB review. The use of the data in this project is authorized under section 45 and approved by ICES{\textquoteright} Privacy and Legal Office.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing agreement The dataset from this study is held securely in coded form at ICES. While legal data sharing agreements between ICES and data providers (e.g., healthcare organizations and government) prohibit ICES from making the dataset publicly available, access may be granted to those who meet prespecified criteria for confidential access, available at www.ices.on.ca/DAS (email: das{at}ices.on.ca). The full dataset creation plan and underlying analytic code are available from the authors upon request, understanding that the computer programs may rely upon coding templates or macros that are unique to ICES and are therefore either inaccessible or may require modification.}, URL = {https://www.medrxiv.org/content/early/2022/11/01/2022.10.31.22281766}, eprint = {https://www.medrxiv.org/content/early/2022/11/01/2022.10.31.22281766.full.pdf}, journal = {medRxiv} }